Research library

B

grade

Lanreotide treatment reduced IGF-1 and GH levels in a patient with a mixed GH/TSH-secreting PitNET, but persistent disease was observed post-surgery.

IGF-1 decreased from 1128 ng/mL to 846 ng/mL after lanreotide treatment.

summary

A

grade

The Rotarix PCV-free vaccine showed non-inferior seroconversion rates compared to the standard Rotarix, but the geometric mean concentration did not meet non-inferiority criteria.

SCR: 84.9% (Rotarix PCV‑free) vs 88.7% (Rotarix); difference -3.73% (95% CI -6.93, -0.55; p = .0317)

summary

A

grade

Orforglipron may help maintain weight loss in patients who have previously used injectable obesity treatments, but further studies are needed to confirm its long-term efficacy.

Cohort 1 maintained an MBE of 74.7% body weight reduction with orforglipron vs 49.2% with placebo at week 52, P<0.001.

summary

B

grade

Lanreotide treatment led to a notable reduction in serum CgA levels in a patient with a duodenal neuroendocrine tumor, but this is based on a single case and requires further investigation.

Serum CgA reduced from 3636 to <100 ng/mL after five months.

summary

B

grade

Acromegaly is often diagnosed late, with overall disease control achieved in 65.5% of patients. Increased awareness among healthcare professionals may help reduce complications.

Overall disease control achieved in 38 patients (65.5%).

summary

C

grade

This study found no evidence of bronchopulmonary neuroendocrine neoplasia in Men1 knockout mice treated with lanreotide, but did observe cases of pulmonary adenocarcinoma in both treated and untreated groups.

No bronchopulmonary neuroendocrine cell hyperplasia or neoplasia detected in 30 mice evaluated.

summary

B

grade

Dyslipidemia may negatively impact progression-free survival in patients with advanced BP-NETs, and atorvastatin therapy could offer some benefit, but further validation is needed.

Not reported in abstract.

summary

B

grade

The Random Forest model showed excellent predictive performance for acute radiation enteritis in cervical cancer patients, but further validation is needed before clinical implementation.

Random Forest model AUC was 0.961.

summary

A

grade

In high-risk pregnant women, the RSVPreF3-Mat vaccine showed an acceptable safety profile and induced strong immune responses, but preterm birth rates were similar to placebo.

Preterm birth occurred in 18.2% and 19.7% of participants in the vaccine and placebo groups, respectively.

summary

B

grade

The adiponectin/leptin ratio may be a useful biomarker for assessing visceral fat accumulation, especially in postmenopausal women, but further prospective studies are needed to confirm these findings.

ALR inversely associated with VAT area in postmenopausal females, p<0.05.

summary

B

grade

Higher red meat intake may reduce fecal incontinence severity, while prolonged sedentary behavior could increase it in colorectal cancer patients post-surgery.

β = -1.42; 95% CI, -2.71 to -0.12 for red meat intake.

summary

C

grade

Maternal diets rich in omega-3 fatty acids may positively influence offspring metabolism and neurodevelopment, but further research is needed to confirm these effects in humans.

Not reported in abstract.

summary

B

grade

The study estimates a total LAR of 90 lung cancer cases per 100,000 persons due to HRCT exposure during the COVID-19 pandemic, highlighting the need for dose optimization in imaging protocols.

Total LAR for lung cancer was 90 (95% UL, 80 - 116) per 100,000 persons.

summary

D

grade

Paltusotine may be a more effective and better-tolerated treatment option for acromegaly compared to some existing therapies, but further clinical experience is needed to confirm these findings.

Paltusotine demonstrated significantly higher biochemical control vs O-OCT and SC-OCT-D (ORs: 7.34 [1.48-36.07] and 7.85 [1.72, 36.25]).

summary

D

grade

Lanreotide showed a significant reduction in total kidney volume after more than 2 years, but its efficacy compared to octreotide and pasireotide remains uncertain.

-7.8 mL TKV reduction for lanreotide after more than 2 years, 95% CI: -10.2 to -5.4

summary

B

grade

Lanreotide therapy maintained stable disease for 18 months in a patient with pancreatic neuroendocrine neoplasm, allowing for successful conversion surgery.

Stable disease maintained for 18 months.

summary

B

grade

This case highlights the rarity of primary hepatic neuroendocrine tumors and the importance of accurate diagnosis and management. Treatment with lanreotide resulted in stable lesions.

Largest hepatic mass measured 195 × 100 × 230 mm.

summary